EUFEST STUDY PDF

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Kigrel Nijar
Country: Uruguay
Language: English (Spanish)
Genre: Automotive
Published (Last): 7 August 2016
Pages: 140
PDF File Size: 9.70 Mb
ePub File Size: 2.88 Mb
ISBN: 895-9-26705-973-1
Downloads: 81461
Price: Free* [*Free Regsitration Required]
Uploader: Dozragore

Rationale and design of the trial. Intolerance to one of the drugs in this study; 4.

These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics. Eligibility Participant inclusion criteria 1.

We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated. SchizophreniaSchizophreniform disorderSchizoaffective disorder.

Eligible patients were aged years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. At regular time intervals patients are followed-up until 12 months after recruitment: Evid Based Ment Health. The presence of one or more of the contraindications against any of the study drugs. What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Result of results found for within. The Lancet ; The primary outcome measure was all-cause treatment discontinuation. Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, eufets, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular eufewt of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

  EPOX EP-4PDA3I MANUAL PDF

The presence of one or more of the contra-indications against any of the study drugs. Ethics approval received from the local medical sttudy committee. Natural history of schizophrenia. Plain English Summary Not provided at time of registration Trial website http: We focus on the real world treatment of first episode patients srudy enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment.

Analysis was by intention to treat. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested.

Schizophreniform or schizoaffective disorder; 3. The primary outcome measure is retention in treatment, defined as time to discontinuation of study drug. What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Amisulpride, Haloperidol, Olanzapine, Quetiapine, Ziprasidone. Genetic determinants of response to antipsychotic drugs 9. Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia patients.

Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Side effects – extrapyramidal eucest EPS side-effect profile, sexual side effects and weight gain 3.

This effort represents the first independently designed trans-European schizophrenia treatment trial. The aim of the European First Episode Schizophrenia Trial EUFEST is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics.

EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia eufrst achievable, for at least 1 year.

  BC458 DATASHEET PDF

We did an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries. Quality of life 6. PfizerAstraZenecaSanofi-Aventis. The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

sstudy

Patients and their treating physicians were not blinded to the assigned treatment. The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia. Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range.

Multicentre, randomised active controlled, parallel group trial. Diagnosis of schizophrenia; 2. Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or acceptance.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Home Who are we? This outcome is assessed at regular time intervals until 12 months after recruitment. Results and Publications Publication and dissemination tsudy Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Publication list 1. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement.

At regular time intervals patients are followed-up until 12 months after recruitment: Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens. Psychopathology fufest positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation 2.